Immunovant, Inc. (IMVT)
32.11
-1.14
(-3.43%)
USD |
NASDAQ |
Oct 06, 16:00
32.20
+0.09
(+0.28%)
After-Hours: 06:41
Immunovant Shareholders Equity (Quarterly) : 735.39M for June 30, 2026
Shareholders Equity (Quarterly) Chart
Historical Shareholders Equity (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | 735.39M |
| March 31, 2026 | 852.59M |
| December 31, 2025 | 986.14M |
| September 30, 2025 | 519.70M |
| June 30, 2025 | 608.54M |
| March 31, 2025 | 707.45M |
| December 31, 2024 | 352.62M |
| September 30, 2024 | 449.05M |
| June 30, 2024 | 544.66M |
| March 31, 2024 | 617.76M |
| December 31, 2023 | 679.34M |
| September 30, 2023 | 251.81M |
| June 30, 2023 | 299.86M |
| March 31, 2023 | 362.49M |
| Date | Value |
|---|---|
| December 31, 2022 | 414.68M |
| September 30, 2022 | 395.75M |
| June 30, 2022 | 436.49M |
| March 31, 2022 | 469.82M |
| December 31, 2021 | 505.15M |
| September 30, 2021 | 536.40M |
| June 30, 2021 | 365.53M |
| March 31, 2021 | 391.48M |
| December 31, 2020 | 414.15M |
| September 30, 2020 | 438.41M |
| June 30, 2020 | 267.78M |
| March 31, 2020 | 94.07M |
| December 31, 2019 | 111.86M |
Shareholders' Equity Definition
Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.
Shareholders Equity (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Shareholders Equity (Quarterly) Benchmarks
| Roivant Sciences Ltd. | 4.231B |
| Moderna, Inc. | 6.761B |
| Altimmune, Inc. | 474.21M |
| Vertex Pharmaceuticals, Inc. | 20.25B |
| First Tracks Biotherapeutics, Inc. | 168.80M |
Shareholders Equity (Quarterly) Related Metrics
| Total Assets (Quarterly) | 852.49M |
| Total Liabilities (Quarterly) | 117.10M |
| Current Ratio | 7.269 |
| Net Debt Paydown Yield | 0.00% |